Legal Representation
Attorney
Michael W. Schroeder
Application History
7 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 3, 2025 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Oct 3, 2025 | GNSL | F | LETTER OF SUSPENSION E-MAILED | Loading... |
| Oct 3, 2025 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Sep 29, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 24, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 15, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| May 15, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Product design and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Product design and development in the field of lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics, including mRNA, siRNA, and DNA; Design and development of software and hardware for optimization and customization of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications; Research and development of technology in the field of artificial intelligence-based software tools for lipid discovery, pharmaceutical formulation, and delivery optimization; Providing temporary use of non-downloadable cloud-based software for designing, modeling, and deploying therapeutic delivery systems; Medical and scientific research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Research and development in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics; Technology consultation and research in the field of lipid nanoparticle (LNP) drug delivery systems for pharmaceutical and therapeutic applications and lipid nanoparticle (LNP) compositions for the delivery of nucleic acid-based therapeutics
First Use Anywhere:
Mar 23, 2023
First Use in Commerce:
Dec 29, 2023
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOSCIENCES"